Background The increase in disease-modifying drugs (DMDs) allows individualization of treatment in relapsing multiple sclerosis (RMS); however, the long-term impact of diferent treatment sequences is not well established. This is particularly relevant for MS patients who may need to postpone more aggressive DMD strategies. Objective To evaluate diferent therapeutic strategies and their long-term outcomes, measured as relapses and confrmed disability progression (CDP), in MS ‘real-world’ settings. Methods Multicentre, observational, retrospectively acquired cohort study evaluating the long-term impact of diferent treatment strategies on disability outcomes in patients with RMS in the Italian MS Register. Results We evaluated 1152 RMS-naïve patients after propensity-score adjustment. Patients included were receiving: interferon beta-1a (IFN-β1a) 44 µg switching to fngolimod (FTY; IFN-switchers; n=97); FTY only (FTY-stayers; n=157); IFN-β1a only (IFN-stayers; n=849). CDP and relapses did not difer between FTY-stayers and IFN-switchers [HR (95% CI) 0.99 (0.48–2.04), p=0.98 and 0.81 (0.42–1.58), p=0.55, respectively]. However, IFN-stayers showed increased risk of relapses compared with FTY-stayers [HR (95% CI) 1.46 (1.00–2.12), p=0.05]. Conclusion The ideal treatment option for MS is becoming increasingly complex, with the need to balance beneft and risks. Our results suggest that starting with FTY afects the long-term disease outcome similarly to escalating from IFN-β1a to FTY

Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register

Paolicelli D.;Manni A.;De Luca G.;De Robertis F.;Iaffaldano A.;Iaffaldano P.;Trojano M.
2019

Abstract

Background The increase in disease-modifying drugs (DMDs) allows individualization of treatment in relapsing multiple sclerosis (RMS); however, the long-term impact of diferent treatment sequences is not well established. This is particularly relevant for MS patients who may need to postpone more aggressive DMD strategies. Objective To evaluate diferent therapeutic strategies and their long-term outcomes, measured as relapses and confrmed disability progression (CDP), in MS ‘real-world’ settings. Methods Multicentre, observational, retrospectively acquired cohort study evaluating the long-term impact of diferent treatment strategies on disability outcomes in patients with RMS in the Italian MS Register. Results We evaluated 1152 RMS-naïve patients after propensity-score adjustment. Patients included were receiving: interferon beta-1a (IFN-β1a) 44 µg switching to fngolimod (FTY; IFN-switchers; n=97); FTY only (FTY-stayers; n=157); IFN-β1a only (IFN-stayers; n=849). CDP and relapses did not difer between FTY-stayers and IFN-switchers [HR (95% CI) 0.99 (0.48–2.04), p=0.98 and 0.81 (0.42–1.58), p=0.55, respectively]. However, IFN-stayers showed increased risk of relapses compared with FTY-stayers [HR (95% CI) 1.46 (1.00–2.12), p=0.05]. Conclusion The ideal treatment option for MS is becoming increasingly complex, with the need to balance beneft and risks. Our results suggest that starting with FTY afects the long-term disease outcome similarly to escalating from IFN-β1a to FTY
File in questo prodotto:
File Dimensione Formato  
paolicelli2019.pdf

non disponibili

Tipologia: Documento in Post-print
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 530.26 kB
Formato Adobe PDF
530.26 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11586/248421
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact